

In one aspect there is provided the compound (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride in crystalline form; wherein said crystalline salt form is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 11.0°, 24.1° and 24.5°, wherein said X-ray powder diffraction diagram is obtained by using combined Cu $K\alpha_1$ and $K\alpha_2$ radiation, without $K\alpha_2$ stripping; and the accuracy of the 2θ values is in the range of $2\theta \pm 0.2^\circ$.

Another aspect relates to a pharmaceutical composition comprising the compound as described above, and a pharmaceutically acceptable carrier.

- 10 Another aspect relates to the compound as disclosed herein for use as a medicament.

Another aspect relates to the use of the compound as disclosed herein for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.

- 15 Another aspect relates to the use of the compound as disclosed herein in the manufacture of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders selected from the group consisting of dyssomnias, parasomnias, and substance-induced sleep disorders; anxiety disorders; and addiction disorder.

Claims

1. The compound (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride in crystalline form; wherein said crystalline salt form is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 11.0° , 24.1° and 24.5° , wherein said X-ray powder diffraction diagram is obtained by using combined Cu $K\alpha_1$ and $K\alpha_2$ radiation, without $K\alpha_2$ stripping; and the accuracy of the 2θ values is in the range of $2\theta \pm 0.2^\circ$.
2. The compound according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 9.2° , 11.0° , 13.8° , 15.1° , 16.3° , 16.8° , 19.8° , 24.1° , 24.5° , and 27.3° , wherein said X-ray powder diffraction diagram is obtained by using combined Cu $K\alpha_1$ and $K\alpha_2$ radiation, without $K\alpha_2$ stripping; and the accuracy of the 2θ values is in the range of $2\theta \pm 0.2^\circ$.
3. The compound according to claims 1 or 2, which essentially shows the X-ray powder diffraction pattern as depicted in Figure 2.
4. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition according to claim 4 for use in the treatment or prevention of a mental health disease or disorder relating to orexinergic dysfunctions.
6. The compound according to any one of claims 1 to 3 for use as a medicament.
7. The compound according to any one of claims 1 to 3 for use in the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.

8. The compound according to any one of claims 1 to 3 for use in the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders selected from the group consisting of dyssomnias, parasomnias, and substance-induced sleep disorders; anxiety disorders; and addiction disorders.
- 5 9. Use of the compound according to any one of claims 1 to 3 for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.
10. Use of the compound according to any one of claims 1 to 3 in the manufacture of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders selected from the group consisting of dyssomnias, parasomnias, and substance-induced sleep disorders; anxiety disorders; and addiction disorders.